Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population‐based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans

4 Nov 2022

Abstract excerpt

INTRODUCTION: African Americans (AAs) and European Americans (EAs) differ in Alzheimer's disease (AD) prevalence, risk factors, and symptomatic presentation and AAs are less likely to enroll in AD clinical trials. METHODS: We conducted race-conscious pharmacoepidemiologic studies of 5.62 million older individuals (age ≥60) to investigate the association of telmisartan exposure and AD outcome using Cox analysis,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dementia and Cognitive Impairment Research
Share to Genetic Associations and Epidemiology
Share to Renin-Angiotensin System Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36331056
DOI: 10.1002/alz.12819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population‐based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African AmericansPMID 36331056Read ↗

Angiotensin-converting enzyme inhibition and Alzheimer’s disease: Findings from proteome-wide Mendelian randomization and a large prospective cohort studySemantic proximity Read ↗

Class-Specific Antihypertensives and Alzheimer's Disease: Genotype- and Hypertension-Stratified Analysis.Semantic proximity Read ↗

Repurposing drugs for the prevention of vascular dementia: Evidence from drug target Mendelian randomizationSemantic proximity Read ↗

Effect of initiating an ARB- versus ACEI-based regimen on dementia risk, a target trial emulation of 2.5 million US VeteransSemantic proximity Read ↗

Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer’s disease: a Mendelian randomization studySemantic proximity Read ↗

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.Semantic proximity Read ↗

Repurposing antihypertensive drugs for the prevention of Alzheimer’s disease: a Mendelian Randomization studySemantic proximity Read ↗

Association of antihypertensive drug target genes with alzheimer's disease: a mendelian randomization study.Semantic proximity Read ↗

Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer's disease: a Mendelian randomization study.Semantic proximity Read ↗

Combining genetics with real-world patient data enables ancestry-specific target identification and drug discovery in Alzheimer’s diseaseSemantic proximity Read ↗

Mendelian randomization study of diabetes and dementia in the Million Veteran ProgramSemantic proximity Read ↗

Computational Approaches to Identification and Characterization of Masitinib as Potential Treatment for Alzheimer's Disease through Molecular Docking and Two-sample Mendelian RandomizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.